Reaction
Intestinal Resection reporting signals
As of the last recalculation, Intestinal Resection appears in 5,278 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB (PRR 40.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Infliximab | 1,573 | 40.0 | 40.3 |
| Risankizumab-Rzaa | 463 | 24.4 | 24.5 |
| Ustekinumab | 509 | 21.6 | 21.7 |
| Infliximab-Dyyb | 136 | 18.8 | 18.9 |
| Azathioprine | 271 | 12.7 | 12.8 |
| Vedolizumab | 261 | 12.5 | 12.6 |
| Cholestyramine | 35 | 11.5 | 11.5 |
| Hydrocortisone Sodium Succinate | 26 | 11.0 | 11.0 |
| Adalimumab | 1,352 | 9.8 | 9.8 |
| Upadacitinib | 155 | 7.7 | 7.7 |
| Mesalamine | 78 | 5.5 | 5.6 |
| Dimenhydrinate | 14 | 5.2 | 5.2 |
| Iron | 75 | 4.5 | 4.5 |
| Mercaptopurine | 19 | 4.3 | 4.3 |
| Diphenoxylate Hydrochloride And Atropine Sulfate | 14 | 4.0 | 4.0 |
| Metronidazole | 60 | 3.7 | 3.7 |
| Certolizumab Pegol | 85 | 2.9 | 2.9 |
| Ciprofloxacin Hydrochloride And Hydrocortisone | 15 | 2.8 | 2.9 |
| Apalutamide | 8 | 2.7 | 2.7 |
| Pancrelipase | 26 | 2.7 | 2.7 |
| Golimumab | 44 | 2.0 | 2.0 |
| Lanreotide Acetate | 4 | 2.0 | 2.0 |
| Niraparib | 11 | 2.0 | 2.0 |
| Linaclotide | 12 | 1.8 | 1.8 |
| Trifluridine And Tipiracil | 3 | 1.1 | 1.1 |
| Relugolix | 4 | 0.7 | 0.7 |
| Copper | 3 | 0.3 | 0.3 |